Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech or the Company, 6990.HK) announced that a new indication ...